Objective: Numerous studies have focused on biomarkers for acute lung injury and acute respiratory distress syndrome. Although several biomarkers have been identified, their relative performance is unclear. We aim to provide a quantitative overview of plasma-derived biomarkers associated with acute respiratory distress syndrome diagnosis or mortality. Data Sources: MEDLINE (inception to January 2012) and personal databases. Study Selection: English-language studies on plasma biomarkers associated with acute respiratory distress syndrome diagnosis or mortality. Data Extraction: Demographic variables, plasma levels of biomarker, statistical data, acute respiratory distress syndrome occurrence, and mortality rates were retrieved. The methodological quality was assessed with the Quality Assessment of Diagnostic Accuracy Studies score. Clinical outcomes included 1) diagnosis of acute respiratory distress syndrome in the at-risk population and 2) mortality in acute respiratory distress syndrome patients. For each biomarker, pooled odds ratios for clinical outcome were calculated by meta-analysis, and biomarkers were ranked according to pooled odds ratio.
Data Synthesis: Fifty-four studies appeared eligible for meta-analysis, together including 3,753 patients. We identified 20 biomarkers for diagnosis of acute respiratory distress syndrome in the at-risk population and 19 biomarkers for mortality of acute respiratory distress syndrome patients. The biomarkers most strongly associated with acute respiratory distress syndrome diagnosis in the at-risk population, when increased, were Krebs von den Lungen-6 (odds ratio [95% CI], 6.1 [3.0-12.1]), lactate dehydrogenase (5.7 [1.7-19.1]), soluble receptor for advanced glycation end products (3.5 [1.7-7.2]), and von Willebrand Factor (3.1 [2.0-5.2]). The biomarkers most strongly associated with acute respiratory distress syndrome mortality, when increased, were interleukin-4 (18.0 [6.0-54.2]), interleukin-2 (11.8 [4.3-32.2] ), angiopoietin-2 (6.4 [1.3-30.4] ), and Krebs von den Lungen-6 (5.1 [3.0-12.2] ). Decreased levels of Protein C were associated with increased odds for acute respiratory distress syndrome diagnosis and mortality. Conclusions: This meta-analysis provides a unique ranking of plasma biomarkers according to their strength of association with acute respiratory distress syndrome diagnosis or acute respiratory distress syndrome mortality. The relative performance of biomarkers among studies shown in this ranking may help to improve acute respiratory distress syndrome diagnosis and outcome prediction. (Crit Care Med 2014; 42:691-700) Key Words: acute lung injury; acute respiratory distress syndrome; diagnosis; mortality; plasma biomarker T he acute respiratory distress syndrome (ARDS) is a clinical syndrome, characterized by tachypnea, severe hypoxemia, decreased respiratory compliance, and lung tissue damage evident from chest radiograph (1) . Although diffuse alveolar damage forms the core pathological process (2), diagnosis of ARDS and its milder form acute lung injury (ALI) are based on clinical characterization. These clinical characteristics are formalized in the American European Consensus Conference (AECC) criteria (3) . However, the accuracy of the AECC criteria has been questioned since their publication in 1994 (4-6), hampering diagnosis of ALI/ARDS.
In addition to a 2012 revision of the clinical criteria for ALI/ARDS, known as "the Berlin definition" (7) studies have focused on the identification of biomarkers to improve classification and definition of ARDS. According to the 2001 National Institutes of Health definition, a biomarker is "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention" (8) . Biomarkers reflect pathophysiological mechanisms and as such may help to recognize ARDS. Combining existing clinical definitions with reliable biomarkers may therefore enhance the diagnosis of ARDS. Besides recognition of ARDS, biomarkers may contribute to risk stratification and prediction of outcome or serve as surrogate endpoints to monitor intervention (9) .
The proposed advantages of biomarkers (9) , together with the limited reliability and validity of the AECC criteria (5, 6) , have spurred the search for reliable ARDS biomarkers in the last two decades. This search has resulted in a large spectrum of ARDS biomarkers, ranging from inflammatory mediators to tissue degradation products and from plasma-derived biomarkers to genetic polymorphisms. Recent reviews have provided excellent narrative overviews of available biomarker studies and their relation to the pathophysiology of ARDS (9, 10) . However, a quantitative review or comparison of the performance of the several biomarkers studied is lacking.
In the current study, we conducted a systematic review and meta-analysis of all studies on plasma biomarkers associated with either diagnosis of ARDS in the at-risk population or ARDS-related mortality. This study provides a quantitative overview of all plasma-derived biomarkers of ARDS studied thus far and may help to establish reliable ARDS biomarkers.
METHODS

Data Source and Study Selection
For this study, a systematic literature search in MEDLINE and personal databases was performed to identify all studies reporting on plasma biomarker in patients with or at risk for ARDS. Details of the search strategy are outlined in the supplemental data (Supplemental Digital Content 1, http://links.lww.com/ CCM/A765). All studies obtained by this search were evaluated for eligibility by two independent researchers (M.L.T., J.A.). In case of disagreement, a third investigator (A.B.J.G.) was consulted. Eligibility of a study for the meta-analysis was based on the following selection criteria: report of original research, inclusion of adults with or at risk for ARDS, report of plasma concentration (absolute values) of a biomarker related to a clinical outcome (occurrence and mortality of ARDS in the study population), description of demographic variables, and written in English. Studies were excluded if they were the only study reporting on a specific biomarker.
Data Extraction and Quality Assessment
In a standardized fashion, the following data were retrieved (by M.L.T., J.A.) from the included studies: data on ARDS etiology, sample size of the subgroups, mean or median plasma level of the biomarker (per subgroup), and p value of the statistical test that was used to compare the subgroups. When in an included study a biomarker was measured more than once, only the baseline measurement (i.e., the first measurement provided) was extracted. In addition, demographic variables (age, sex, and total number of participants), the diagnostic criteria used for ARDS diagnosis, mortality, and the moment of biomarker sampling were retrieved.
All studies were assessed on methodological quality according to the QUADAS score, which varies between 0 and 14 (11) (supplemental data, Supplemental Digital Content 1, http:// links.lww.com/CCM/A765). The meta-analysis and reporting of the data were performed according to the Proposal for Reporting Meta-analysis of Observational Studies in Epidemiology (12) .
Data Synthesis and Analysis
Two types of clinical outcomes were considered in this study: 1) diagnosis of ARDS in the at-risk population and 2) mortality of patients in the ARDS population. To analyze the strength of association of a biomarker with clinical outcome, we extracted plasma levels of the biomarker from different subgroups: ARDS patients versus critically ill non-ARDS patients (for association with ARDS diagnosis in the at-risk population) or survivors versus nonsurvivors in a cohort of ARDS patients (for association with ARDS mortality among ARDS patients). Studies comparing ARDS patients with healthy controls were excluded for reasons of comparability. The authors' definition of ARDS as given in the articles was taken.
Statistics
Meta-analyses were performed with Comprehensive Meta-Analysis version 2.2 (Biostat, Englewood, NJ) using a randomized model. To determine the strength of association of a specific biomarker with clinical outcome, the following statistical procedure was performed: For each study, we calculated the standardized difference of the mean in biomarker levels between the subgroups relevant for clinical outcome (subgroups: no ARDS vs ARDS, survivors vs nonsurvivors). The standardized difference of the mean is based on the exact p value and the population size and allows subsequent calculation of the odds ratio (OR) of the specific biomarker for clinical outcome. Subsequently, the pooled OR of different studies on a biomarker was calculated. Data are presented as OR with 95% CI. Forest plots are provided for biomarkers of which five or more studies are included in the meta-analysis. Biomarkers were ranked according to OR and statistical significance. I 2 and Tau 2 statistics were performed to assess heterogeneity among studies. Funnel plots were created to evaluate publication bias, which was further analyzed with Egger regression test (13), Duval and Tweedie's trim and fill (14) , and Orwin's failsafe N test (15) . For Orwin's fail-safe N test, the clinically trivial OR value was arbitrarily set at 1.25 for OR greater than 1 or at 0.8 for OR less than 1.
With SPSS (SPSS 20, IBM Corporation, Armonk, NY), the weighted average of each biomarker was calculated for the subgroups mentioned before, based on the average value provided in a study (mean and median were considered here as equal, i.e., value most representative for a specific population) and the size of the study population. Weighted averages are presented as mean ± SD and range. Exact p values are given unless less than 0.001. A p value of less than 0.05 was considered statistically significant, except for Egger regression test in which a p value of less than 0.10 was considered statistically significant.
RESULTS
Literature Search
The MEDLINE search yielded 509 articles, whereas the search of personal databases yielded 253 articles. From the initial 762 studies, 672 studies were excluded because of duplicate studies (n = 243), other language than English (n = 49), lack of focus on ARDS (n = 73), in vitro/animal studies (n = 86), no original research (reviews, editorials, or case reports, n = 49), pediatric studies (n = 22), no biomarker measurement in plasma (n = 61), no relation of biomarker with occurrence or mortality of ARDS as clinical outcome (n = 56), use of biomarker for treatment monitoring (n = 18), or insufficient data (absolute plasma concentrations or p values, n = 13). From one study, no full text copy was available despite attempts to contact the authors (16) . After removal of these studies, 91 studies were found eligible for data retrieval. Of these 91 studies, 37 studies were the only studies that reported on a specific biomarker, precluding meta-analysis. The remaining 54 articles were used for meta-analysis ( Fig. 1) .
Study Characteristics and Quality Assessment
Demographic variables of the included studies are presented in Supplemental Table 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/A765). In total, 3,753 patients were included. Only adult studies were considered, resulting in an age range from 33 to 78 years. In the majority of studies, ALI or ARDS was diagnosed according to the AECC criteria (41 of 54). Alternative criteria involved the lung injury score (7 of 54) (71), the ratio of protein in edema fluid/protein in plasma (3 of 54), the so-called Fowler criteria (3 of 54) (72), or non-formalized clinical criteria (5 of 54). The mortality in the selected studies ranged from 0% to 70%. The time point on which plasma samples were taken for biomarker detection varied from 0 to 72 hours after ICU admission (Supplemental Table 1 
Biomarkers Associated With ARDS Diagnosis in the At-Risk Population
We performed meta-analyses on 20 different plasma biomarkers that were associated with the diagnosis ARDS in the at-risk population ( Table 1) . For four of these biomarkers (von Willebrand factor [vWF], soluble receptor for advanced glycation end products [sRAGE], interleukin [IL]-6, and tumor necrosis factor-α [TNF-α]), greater than or equal to five studies per biomarker were identified. For the other biomarkers, only two to four studies per biomarker were found. The pooled ORs for the presence of ARDS in the at-risk population are summarized and ranked in Table 1 . The highest pooled ORs were observed for Krebs von den Lungen-6 (KL-6), lactate dehydrogenase (LDH), sRAGE, vWF, and IL-8. Figure 2 shows forest plots of the biomarkers with data available of at least five studies (Fig. 2) . For almost all biomarkers, an elevated plasma concentration was associated with increased odds for ARDS (OR > 1). Otherwise, decreased plasma concentrations of transferrin and protein C were associated with increased odds (OR < 1) for ARDS. For Clara Cell-16, C-reactive protein, and intercellular adhesion molecule-1, no significant OR for ARDS diagnosis was found. Among biomarkers with significant OR for ARDS diagnosis, no significant heterogeneity was observed ( Table 1) .
Biomarkers Associated With ARDS Mortality
We performed meta-analyses on 19 biomarkers reported to be associated with ARDS mortality. For four of these biomarkers (IL-1β, TNF-α, IL-8, and IL-6), greater than or equal to five studies per biomarker were identified. For the remaining biomarkers, two to four studies per biomarker were found ( Table 2 ). The pooled ORs for ARDS mortality are ranked in Table 2 . Biomarkers with the highest ORs for mortality were IL-4, IL-2, angiopoietin (Ang)-2, and KL-6. Figure 3 shows forest plots of the pooled OR of IL-1β, TNF-α, IL-8, and IL-6 for ARDS mortality. Protein C was the only biomarker of which decreased plasma levels were associated with increased odds for ARDS mortality. For procalcitonin, plasminogen activator inhibitor-1, IL-10, Clara Cell-16, sRAGE, and surfactant protein-A, no significant OR for ARDS mortality was found.
For six biomarkers (IL-1β, TNF-α, IL-8, vWF, IL-6, and protein C), significant heterogeneity was observed. Evaluating heterogeneity, we found that it was predominantly caused by a limited number of studies, which reported extreme ORs (27, 46, 47, 63) . Excluding the studies with extreme ORs (arbitrarily chosen as OR < 0.10 or OR > 10.0) diminished heterogeneity, whereas the pooled OR remained significant for all biomarkers except IL-1β ( Table 3) . 
Weighted Average of Biomarkers per Subgroup
To provide insight in the absolute plasma concentrations of the biomarkers included in this meta-analysis, we calculated the mean values of the plasma concentration provided in each study. Supplemental 
Evaluation of Publication Bias
Egger regression test revealed that for a number of biomarkers, there was a significant association between effect size and precision; among biomarkers associated with ARDS diagnosis, a p value of less than 0.10 was found for IL-8 and TNFα, whereas among biomarkers associated with mortality, a p value of less than 0.10 was found for IL-1β, TNF-α, IL-8, and IL-6. However, when we adjusted for possible publication bias by Duval and Tweedie's trim and fill, the OR remained statistically significant for all biomarkers. The relatively large number of missing studies required to bring these ORs to a clinically trivial value, as calculated with Orwin's fail-safe N test, suggest that the chance that the entire effect observed in our study is a matter of bias, is small (Supplemental Table 5 
DISCUSSION
In the current study, we performed a meta-analysis of publications reporting on plasma biomarkers for their strength of association with ARDS in the at-risk population or ARDS mortality among ARDS patients. Searching MEDLINE and personal databases, we identified 54 publications, together including 3,753 patients with or at risk for ARDS. We show that increased plasma levels of KL-6, LDH, sRAGE, and vWF are most strongly associated with ARDS diagnosis in the at-risk population, whereas the strongest association with ARDS mortality was found for IL-4, IL-2, Ang-2, and KL-6. Increased plasma levels of transferrin and protein C were associated with decreased odds for both clinical outcomes. This unique ranking of ARDS plasma biomarker according to their strength of association may help to establish reliable ARDS biomarkers. This is the first study providing a quantitative overview of biomarker research in ARDS performed thus far. Collecting data from almost 4,000 patients we ranked reported biomarkers according to their pooled OR for ARDS diagnosis or mortality. This study may serve ARDS biomarker research in several ways. First, it provides a novel manner to study different biomarkers for the same clinical outcome. The calculation of the standardized difference of the means allows inclusion of various studies-even when absolute predictive values such as sensitivity and specificity are not provided-and provides a measure to compare mutual performance. Second, this study provides a synthesis of ARDS plasma biomarker research performed in the last 2 decades. It demonstrates not only which plasma biomarkers have drawn more attention and which less but also which plasma biomarkers perform better over various studies. The ranking provided in this study may therefore guide future biomarker research, both in decisions on prospective biomarker testing, and in composition of biomarker panels. Combining multiple biomarkers has previously been shown to enhance diagnostic accuracy (62, 73) .
In addition, the ranking of plasma biomarkers may elucidate the pathophysiology of ARDS. The biomarkers most strongly associated with ARDS diagnosis ( Table 2) alveolocapillary unit is reflected by release of KL-6 into lung interstitial lining fluid and the circulation (20, 50, 74) , while inflammatory activation of the endothelial side is characterized by endothelial presentation of selectins on the cell surface and release of proteins such as soluble selectins, Ang-2, and vWF into the circulation (26, 75, 76) . The association of Ang-2 with ALI was confirmed in a very recent study (77) . Otherwise, among the five biomarkers most strongly associated with ARDS mortality, three were proinflammatory cytokines (IL-4, IL-2, and IL-1β), known to reflect systemic inflammation. It is conceivable, however, that severity of the underlying condition, for example, sepsis, contributes to mortality independent of respiratory failure. Unfortunately, lack of data precluded analysis of these confounding effects. In terms of plasma biomarker performance, our study therefore indicates that ARDS diagnosis correlates with tissue damage, whereas ARDS mortality correlates more with markers of systemic inflammation. Some considerations should be taken into account when evaluating the biomarker ranking provided in this study. Because not all studies provided absolute predictive values such as sensitivity and specificity, the ranking in our study is based on OR. ORs may be difficult to interpret and should be approached with care when applied to clinical practice (78) . Yet, for the goal of the current study, that is, ranking of biomarker performance, the OR suffices and allows inclusion of a higher number of studies. Second, in this meta-analysis, only biomarkers addressed by multiple studies (≥ 2) were included. Because of this method, biomarkers evaluated in a single study, even though promising, are not considered, which may limit the view on plasma biomarker research as a whole. Third, in the study of biomarkers for diagnostic utility, the choice of proper controls remains a matter of debate. One side of the discussion clings to the argument that critically ill patients at risk for ARDS (due to the presence of ARDS risk factors) form the proper controls, whereas the other side of the discussion clings to the presence of edema (resulting from other causes than increased permeability, c.q. hydrostatic edema) as the right control. A drawback of the latter is that patients with hydrostatic edema may not be at risk for ARDS per se, yielding the possibility that a biomarker predicts the risk factor for ARDS instead of ARDS. In the current study, seven (out of 29) of the studies used for the meta-analysis of biomarkers associated with ARDS diagnosis reported on critically ill patients with hydrostatic edema as controls (25, 31, 39, 41, 42, 44, 45) . Post hoc analysis revealed that omission of these studies from the meta-analyses did not affect the magnitude or significance of the ORs presented in Table 1 (data not shown). Fourth, this meta-analysis considers the performance of ARDS biomarkers measured in plasma. A poor performance of a biomarker in the current study, however, does not exclude high performance of the same biomarker when measured in other compartments, such as bronchoalveolar fluid or exhaled gas, as recently shown for low-density lipoprotein receptor-related protein-1 (79). The reason to limit our research focus to plasma-derived biomarkers is that plasma-derived biomarkers have been studied most extensively and that plasma sampling is often part of routine patient management. The fourth consideration is the question of biomarker reliability. The performance of a biomarker depends not only on its strength of association (for this study a high OR) but also on the reproducibility of results (10) . The performance in the ranking of Tables 1 and 2 should therefore be weighed against the number of studies in which this pooled OR was observed. In this aspect, biomarkers such as KL-6, vWF, RAGE, IL-8, and IL-6 (for ARDS diagnosis in the at-risk population) and biomarkers such as TNF-α and Il-8 (for ARDS mortality) can be considered most reliable, as relatively high pooled ORs were calculated from multiple studies. This meta-analysis carries limitations. Since calculation of the OR was among others based on the exact p value, studies with nonsignificant findings are more likely to drop out than studies with significant findings, which may lead to publication bias. This was the case in only eight studies for 11 biomarkers (18, 33, (80) (81) (82) (83) . To provide insight into the biomarkers and studies possibly involved, we summarized these studies in Supplemental ). These tests evaluate the chance but cannot fully exclude the possibility of publication bias. Although Egger test was statistically significant in the meta-analysis of a number of biomarkers, adjustment for this possibility (by Duval and Tweedie's trim and fill) hardly affected the ORs of these biomarkers. Alternatively, a statistically significant Egger test may result from true heterogeneity (84) . Several factors may contribute to heterogeneity: the various etiologies of ARDS (Supplemental Table 2 , Supplemental Digital Content 1, http://links.lww.com/CCM/A765), different methodology for biomarker measurement, the relatively wide range of the interval between study inclusion and biomarker measurement (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/A765), and the large time window in which included studies were published. During this period (1990-2011), changes in ARDS treatment and biomarker assays may have altered biomarker performance. We identified a small number of studies that reported extreme ORs (OR < 0.10 or OR > 10.0) ( Table 3 ). Although we could not identify a common denominator for the studies with extreme ORs, small sample size or age of the study may form an explanation. Despite these factors, no significant heterogeneity was found for biomarkers associated with ARDS diagnosis, whereas only mild heterogeneity was found for some biomarkers associated with ARDS mortality. Correction for the latter did not affect the ORs of these biomarkers (Table 3 ).
In conclusion, including 54 studies and 3,753 patients, this study provides an overview of the research performed after plasma-derived biomarkers for ARDS. The ranking of biomarkers according to their association with ARDS diagnosis in the at-risk population or ARDS mortality may help to improve ARDS diagnosis and outcome prediction. 
